Previous 10 | Next 10 |
Celcuity press release ( NASDAQ: CELC ): Q2 GAAP EPS of -$0.55. At June 30, 2022, Celcuity had cash and cash equivalents of $66.9 million, compared to cash and cash equivalents of $84.3 million at December 31, 2021. For further details see: Celcuity GAAP EPS of -...
Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancer Entered into agreements for the private placement sale of $100 million of equity and to increase available debt facility from $25 million to $75 million The Phase 3 VICTORIA-1 c...
MINNEAPOLIS, MN / ACCESSWIRE / August 4, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that it will release its financial results for the second quarter 2022 after the sto...
MINNEAPOLIS, MN / ACCESSWIRE / August 3, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference to be hel...
Shares of micro-cap company Celcuity ( NASDAQ: CELC ) added 12.7% to $10.42 after hours on Monday as the clinical stage biotech was granted a Breakthrough Therapy designation by the U.S. FDA for its breast cancer treatment gedatolisib. The U.S. drug regulator granted g...
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted gedatolisib Breakthrough...
MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, an...
Celcuity Inc. (CELC) Q1 2022 Earnings Conference Call May 16, 2022 16:30 ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder, Chairman & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jeffe...
Celcuity press release (NASDAQ:CELC): Non-GAAP EPS of -$0.47. Net loss of $7.9M For further details see: Celcuity Non-GAAP EPS of -$0.47
Entered into $100 Million Private Placement Agreement Finalized pivotal Phase 3 trial design for gedatolisib Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer Management to host webcast and conference call today, May 16, 2022, at 4:30 p.m...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...